3647 results for «686»

Filter By

3647 results

Addressing difficult anatomy in STEMI patients

21 May 2026 – From EuroPCR 2026

This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.

FFR and non-hyperaemic pressure ratios

20 May 2026 – From EuroPCR 2026

This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.

Other right-sided and tricuspid valve interventions

20 May 2026 – From EuroPCR 2026

This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.

Insights from real world TAVI practice

20 May 2026 – From EuroPCR 2026

This session presents comprehensive insights from real-world transcatheter aortic valve implantation (TAVI) practice, including sex differences in coronary assessment, the impact of general anesthesia on aortic valve gradients, early rehospitalisation rates, and the management of TAVI in patients with prior hip arthroplasty. Additionally, it explores multinational...

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

18 May 2021

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Authors :

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial

26 Aug 2023

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Nicola Ryan

Author

Nicola Ryan
BIOFLOW DAPT - Biodegradable polymer SES vs durable polymer ZES in HBR subjects with 1-month DAPT
Didn’t find what you were looking for?